Your physician may recommend infusion treatments when you no longer respond to other medications and therapies. Unlike conventional medications that you may take orally as a daily pill, infusion treatments are given through an intravenous line (IV) once every several weeks. (The schedule depends on the type of infusion treatment.)
Infusion treatment at Henry Ford IBD Center
We make every effort to make sure our schedule is convenient for your lifestyle. We offer on-site and after-hours infusion treatments of many medications used to treat IBD, including:
Entyvio® (vedolizumab) has been approved (May, 2014) for the treatment of adults with moderate to severe Crohn’s disease and ulcerative colitis. The medication works to block important contributors to chronic inflammation.
Entyvio offers patients with ulcerative colitis and Crohn's disease a new treatment option, when one or more standard therapies have not done enough to treat their symptoms.
Entyvio injections are given to patients over a period of about 30 minutes. Your doctor will monitor you during and after the infusion treatment for any potential side effects to the medication.
Infliximab (Remicade®) has been approved for the treatment and maintenance of:
- Remission of moderately to severely active Crohn’s disease
- Ulcerative colitis that is unresponsive to conventional therapy
- Fistulizing Crohn’s disease (Fistulas are abnormal channels between two loops of intestine, or between the intestine and another structure, such as the skin.)
Infliximab is approved for the treatment of adults and children over the age of 6. Infusions take about two hours to complete and usually are given every eight weeks.
Natalizumab (Tysabri®) has been approved for inducing and maintaining remission in adult patients with moderately to severely active Crohn’s disease. We offer this medication is to patients who have evidence of inflammation and who do not respond to, or are unable to tolerate, conventional therapies, including inhibitors of TNF-alpha.
We offer Tysabri at our infusion center approximately once every four weeks. It takes about one hour to receive the entire dose.
Certolizumab pegol (Cimzia®) is used to reduce the signs and symptoms of moderately to severely active Crohn’s disease in adult patients who have not been helped enough by usual treatments. Certolizumab pegol is a partial antibody that is bound to a special chemical called polyethylene glycol (PEG), which delays its excretion from the body.
Patients treated with certolizumab pegol receive an injection at our infusion center every two weeks for the first three injections. Once patients start to see the full benefits of the medication, they typically receive Cimzia® once every four weeks.
Methotrexate belongs to the class of drugs known as antimetabolites. Antimetabolites impede the body’s natural chemical processes, such as DNA production and cell division. They are helpful in cancer treatments, as they will prevent cancer cells from thriving, and has also been found useful for treating some cases of Crohn’s disease and rheumatoid arthritis.
Methotrexate may take several weeks to be effective in treating Crohn’s disease. It should only be taken for a long period of time (months or years) under the close supervision of a physician.